Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.
Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles
Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.
She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.
Canada G1E 7G9
- Fortin, PatrickMaster studentCHUL+1 418-525-4444, extension 42296
2705, boulevard Laurier
Canada G1V 4G2
- Razafimandimby, HarimahefaMaster firstname.lastname@example.org
- Verret, PhilipMaster email@example.com
[Factors determining utilization of a Web site by parents in order to report side effects of vaccines]Journal Article
Can J Public Health, 99 (6), 2008.
[Do you counsel your patients on their health behaviors?]Journal Article
Can J Public Health, 99 (1), 2008.
Rapport d'évaluation d'une intervention réalisée auprès des médecins oeuvrant en cabinet privé dans la région de la Capitale-Nationale : 0-5-30 Combinaison PréventionBook
Direction régionale de santé publique, Agence de la santé et des services sociaux de la Capitale-Nationale, Québec, QC, 2007, ISBN: 9782894963494.
Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, CanadaJournal Article
BMC Public Health, 7 , 2007.
Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefsJournal Article
Vaccine, 25 (45), 2007.
An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facilityJournal Article
Clin Infect Dis, 44 (9), 2007.
Habitudes de vie et poids : état de situation, programmes en place et défis pour la région de la Capitale-NationaleBook
Agence de la santé et des services sociaux de la Capitale nationale, Direction régionale de santé publique, Québec, QC, 2006, ISBN: 9782894963104.
L'infirmière et la vaccination : constats et recommandationsBook
Institut national de santé publique, Montréal, QC, 2006, ISBN: 2550470648.
- Durée de l'efficacité d'un calendrier de vaccination à deux doses contre les VPH et la plus-value d'une dose de rappel : diffusion des résultats clés de l'étude ICI-VPH pour soutenir la prise de décision, from 2022-02-02 to 2024-03-30
- HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
Recently finished projects
- Évaluation de l'efficacité du programme québécois de vaccination contre le VPH : Étude de prévalence des types de VPH au Québec chez les garçons de 17 à 20 ans, from 2021-03-09 to 2022-05-31